{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:40:53Z","timestamp":1761154853062},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1016\/j.jbspin.2005.12.003","type":"journal-article","created":{"date-parts":[[2006,1,7]],"date-time":"2006-01-07T12:22:01Z","timestamp":1136636521000},"page":"363-368","source":"Crossref","is-referenced-by-count":19,"title":["Treatment of\u00a0systemic sclerosis"],"prefix":"10.1016","volume":"73","author":[{"given":"Yannick","family":"Allanore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Kahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2005.12.003_bib1","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"1","author":"LeRoy","year":"1988","journal-title":"J. Rheumatol."},{"issue":"Suppl","key":"10.1016\/j.jbspin.2005.12.003_bib2","first-page":"S2","article-title":"The assessment of the patient with systemic sclerosis","volume":"21","author":"Valentini","year":"2003","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jbspin.2005.12.003_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.amjmed.2004.04.031","article-title":"Mortality in systemic sclerosis: an international meta-analysis of individual patient data","volume":"118","author":"Ioannidis","year":"2005","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jbspin.2005.12.003_bib4","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00005792-200203000-00005","article-title":"Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival","volume":"81","author":"Scussel-Lonzetti","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jbspin.2005.12.003_bib5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005792-200203000-00004","article-title":"Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSScS). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients","volume":"81","author":"Ferri","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jbspin.2005.12.003_bib6","doi-asserted-by":"crossref","first-page":"352","DOI":"10.7326\/0003-4819-113-5-352","article-title":"Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors","volume":"113","author":"Steen","year":"1990","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jbspin.2005.12.003_bib7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0889-857X(03)00016-4","article-title":"Scleroderma renal crisis","volume":"29","author":"Steen","year":"2003","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"10.1016\/j.jbspin.2005.12.003_bib8","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1002\/art.10589","article-title":"Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose d-penicillamine in early diffuse systemic sclerosis trial","volume":"46","author":"DeMarco","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2005.12.003_bib9","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/ard.62.11.1088","article-title":"Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach","volume":"62","author":"Mukerjee","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jbspin.2005.12.003_bib10","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1002\/art.11345","article-title":"N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers","volume":"48","author":"Allanore","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2005.12.003_bib11","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/art.10775","article-title":"Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement","volume":"48","author":"Steen","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2005.12.003_bib12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1056\/NEJM199801293380501","article-title":"Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension","volume":"338","author":"McLaughlin","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbspin.2005.12.003_bib13","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1164\/rccm.200204-333OC","article-title":"Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol","volume":"167","author":"Kuhn","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jbspin.2005.12.003_bib14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jbspin.2005.12.003_bib15","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbspin.2005.12.003_bib16","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbspin.2005.12.003_bib17","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1183\/09031936.05.00054804","article-title":"Survival with first-line bosentan in patients with primary pulmonary hypertension","volume":"25","author":"McLaughlin","year":"2005","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jbspin.2005.12.003_bib18","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1378\/chest.126.4.1377","article-title":"Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study","volume":"126","author":"Langleben","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.jbspin.2005.12.003_bib19","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1164\/rccm.200410-1411OC","article-title":"Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study","volume":"171","author":"Wilkins","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jbspin.2005.12.003_bib20","doi-asserted-by":"crossref","first-page":"947","DOI":"10.7326\/0003-4819-132-12-200006200-00004","article-title":"Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis","volume":"132","author":"White","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jbspin.2005.12.003_bib21","first-page":"573","article-title":"Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results","volume":"22","author":"Airo","year":"2004","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jbspin.2005.12.003_bib22","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/art.1780280607","article-title":"Decreased coronary reserve in primary scleroderma myocardial disease","volume":"28","author":"Kahan","year":"1985","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2005.12.003_bib23","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJM198605293142201","article-title":"Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis","volume":"314","author":"Kahan","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbspin.2005.12.003_bib24","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/art.1780340211","article-title":"The effect of nifedipine on myocardial perfusion and metabolism in systemic sclerosis: a positron emission tomographic study","volume":"34","author":"Duboc","year":"1991","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2005.12.003_bib25","first-page":"1941","article-title":"High prevalence of right ventricular systolic dysfunction in early systemic sclerosis","volume":"31","author":"Meune","year":"2004","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jbspin.2005.12.003_bib26","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1136\/ard.2004.031484","article-title":"Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis","volume":"64","author":"Vignaux","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jbspin.2005.12.003_bib27","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/clpt.1990.61","article-title":"The effect of captopril on thallium 201 myocardial perfusion in systemic sclerosis","volume":"47","author":"Kahan","year":"1990","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jbspin.2005.12.003_bib28","first-page":"337","article-title":"Controlled study of nifedipine in the treatment of Raynaud\u2019s phenomenon","volume":"49","author":"Kahan","year":"1982","journal-title":"Rev. Rhum. Mal. Osteoartic."},{"key":"10.1016\/j.jbspin.2005.12.003_bib29","doi-asserted-by":"crossref","first-page":"R309","DOI":"10.1186\/ar1183","article-title":"Nifedipine decreases sVCAM-1 concentrations and oxidative stress in systemic sclerosis but does not affect the concentrations of vascular endothelial growth factor or its soluble receptor 1","volume":"6","author":"Allanore","year":"2004","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jbspin.2005.12.003_bib30","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.amjmed.2003.11.022","article-title":"Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis","volume":"116","author":"Allanore","year":"2004","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jbspin.2005.12.003_bib31","doi-asserted-by":"crossref","first-page":"R93","DOI":"10.1186\/ar1457","article-title":"Nifedipine protects against overproduction of superoxide anion by monocytes from patients with systemic sclerosis","volume":"7","author":"Allanore","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jbspin.2005.12.003_bib32","first-page":"4","article-title":"The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis","volume":"19","author":"Herrick","year":"2001","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jbspin.2005.12.003_bib33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1172\/JCI12020","article-title":"Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients","volume":"108","author":"Stratton","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jbspin.2005.12.003_bib34","first-page":"503","article-title":"Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud\u2019s phenomenon. A randomized, controlled study","volume":"19","author":"Scorza","year":"2001","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jbspin.2005.12.003_bib35","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/PL00011223","article-title":"Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3\u00a0years","volume":"21","author":"Bettoni","year":"2002","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jbspin.2005.12.003_bib36","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/art.20676","article-title":"Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist","volume":"50","author":"Korn","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2005.12.003_bib37","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.amjcard.2003.08.013","article-title":"Effects of cilostazol in patients with Raynaud\u2019s syndrome","volume":"92","author":"Rajagopalan","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.jbspin.2005.12.003_bib38","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1002\/art.20665","article-title":"Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study","volume":"50","author":"Wise","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2005.12.003_bib39","first-page":"1788","article-title":"A systematic review of the outcomes of digital sympathectomy for treatment of chronic digital ischemia","volume":"30","author":"Kotsis","year":"2003","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jbspin.2005.12.003_bib40","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1002\/1529-0131(200112)44:12<2828::AID-ART470>3.0.CO;2-U","article-title":"Improvement in skin thickening in systemic sclerosis associated with improved survival","volume":"44","author":"Steen","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2005.12.003_bib41","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/1529-0131(199906)42:6<1194::AID-ANR16>3.0.CO;2-7","article-title":"High-dose versus low-dose d-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial","volume":"42","author":"Clements","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2005.12.003_bib42","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","article-title":"A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma","volume":"44","author":"Pope","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2005.12.003_bib43","doi-asserted-by":"crossref","first-page":"871","DOI":"10.7326\/0003-4819-132-11-200006060-00004","article-title":"Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial","volume":"132","author":"Seibold","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jbspin.2005.12.003_bib44","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/art.20036","article-title":"Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial","volume":"50","author":"Mayes","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2005.12.003_bib45","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0002-9343(89)80150-0","article-title":"Recombinant interferon-gamma in the treatment of systemic sclerosis","volume":"87","author":"Kahan","year":"1989","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jbspin.2005.12.003_bib46","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1046\/j.1365-2133.1998.02460.x","article-title":"Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial","volume":"139","author":"Grassegger","year":"1998","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jbspin.2005.12.003_bib47","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1529-0131(199902)42:2<299::AID-ANR12>3.0.CO;2-R","article-title":"Interferon-alpha doest not improve outcome at one year in patients with diffuse scleroderma: results from a randomized double-blind, placebo-controled trial","volume":"42","author":"Black","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2005.12.003_bib48","unstructured":"Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM. et\u00a0al. Anti-TGF\u03b21 therapy for diffuse cutaneous systemic sclerosis: a multicenter, randomized, placebo-controlled Phase I\/II Trial of CAT-192. Arthritis Rheum 2004;50: abstract 1851."},{"key":"10.1016\/j.jbspin.2005.12.003_bib49","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/rheumatology\/39.8.865","article-title":"Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma","volume":"39","author":"Morton","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2005.12.003_bib50","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/ard.2003.011205","article-title":"Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT\/EULAR Registry","volume":"63","author":"Farge","year":"2004","journal-title":"Ann. Rheum. Dis."}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X05002228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X05002228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T06:58:42Z","timestamp":1547881122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X05002228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S1297319X05002228"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2005.12.003","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}